Gumintad, Elita L.
HRN: 21-62-66 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/20/2022
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
10/20/2022
10/26/2022
IV
500 Mg
Q 8 Hrs
Amebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes